ClinicalTrials.gg
RecruitingNCT05909033Updated Jun 18, 2023

Early Predictors for the Short Term Native Liver Survival in Patients With Biliary Atresia After Kasai Procedure

An observational study in Biliary Atresia, sponsored by Weibing Tang. Recruiting at 1 site in China. Open to participants aged 6 Months to 6 Years. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Weibing Tang · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2023, 3 years 4 months ago, but the record still lists the study as recruiting.
  • Started May 2017; still recruiting 9 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
150
Ages
6 Months to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Biliary Atresia with a site in China — 7 open to participants now, 9 under way, 1 of them phase 3. Biliary Atresia · China.

Planned enrollment
8th of 10
150 · median 200
Started
2017
the only one that year
Observational
10 of 21
5 open now
Registered
15th of 21
by date

Among the 21 studies in Biliary Atresia with a site in China, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2017, is one of 10 observational ones, and was the 15th registered.

Biliary Atresia

78 studies on the registry are indexed under Biliary Atresia; 26 are open to participants now.

Browse Biliary Atresia studies →

Open to participants now

7 of the 21 studies in Biliary Atresia with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 21 Biliary Atresia studies recruiting now, 3 (14%) set no upper age limit and 18 (86%) stop at 75 or younger; 21 take children under 18; 6 take healthy volunteers.

This study: 6 Months to 6 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Biliary Atresia with a site in China, or all of them as a file.
02

Study summary

Many factors have been proven that may affect NLS in BA patients after KP;however,the early predictors for NLS were not be finally detected.This study was designed to evaluate and identify the preoperative and early postoperative factors associated with NLS for early prediction in BA patients after KP.

Read the detailed description

Biliary atresia (BA) is the most common cause of neonatal cholestasis, occurring in approximately 1: 8000 to 1:15000 in Asian populations compared with those in Europe and the USA, with a ratio of 1: 1.56 in males and females.Until now, Kasai procedure(KP) remains the preferred treatment for biliary BA;however,nearly 60-70% patients after KP need liver transplants to achieve long-term survival.Therefore, it is meaningful to seek and analyze the factors affecting the native liver survival(NLS) in BA patients with KP for prediction. Luckily, A lot of studies have designed to seek the risk factors for death or liver transplants in BA patients after KP,and many factors have been proven that may affect NLS,including old age at KP,low gamma-glutamyl transpeptidase(GGT) level,Cytomegalovirus(CMV) Infection,early jaundice clearance(JC) and postoperative cholangitis(PC),etal.However,the predictors for NLS were not be finally detected.Otherwise,the safety of liver transplants has been improved in the past few years and performing liver transplant in young infants has been proven to be feasible.Then,it is important to seek early NLS predictors for counseling the necessity and timing of liver transplant.Unfortunately,early predictors of NLS focus on preoperative and early postoperative period after KP were insufficient.

This study is primarily designed to evaluate and identify the preoperative and early postoperative factors associated with NLS for early prediction in BA patients after KP.

03

Conditions studied

  • Biliary Atresia

Browse trials for

Keywords

  • biliary Atresia
  • Kasai procedure
  • early predictor
  • native liver survival
04

Who can participate

Ages eligible
6 Months to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients with Biliary atreisa and were performed with kasai procedures

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Biliary Atresia(BA) patients performed with Kasai Procedure patients completed the follow-up>6 months

Exclusion criteria

Exclusion Criteria:

BA patients without KP patients lost of follow-up BA patients with other severe complications lead to death

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
150 participants (estimated)
Patient registry
No

Interventions

  • ProcedureKasai procedure

    All KPs were performed by a medical team. This technique involved creation of a 35-40 cm Roux loop to facilitate biliary drainage. After dissection of the hepatic vasculature at the hilum and excision of the hilar plate, hepaticojejunostomy was performed as an anastomosis extending from the bifurcation of the right hepatic artery into anterior and posterior branches to the Rex confluence of the left portal vein with the obliterated umbilical vein.

06

What researchers measure

Primary outcomes

  1. NLS rate

    native liver survival rate

    Time frame: through study completion, an average of 3 years

Secondary outcomes

  1. age at KP

    age at kasai procedure

    Time frame: through study completion, an average of 3 years

  2. PC

    post cholangitis

    Time frame: through study completion, an average of 3 years

  3. JC

    jaudiance clearance

    Time frame: through study completion, an average of 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2017 (actual). Primary completion is estimated for Jul 2023, 73 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2023
First posted
Jun 18, 2023
StartActual
May 20, 2017
Primary completionEst.
Jul 1, 2023
CompletionEst.
Jul 1, 2023
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05909033
Lead sponsor
Weibing Tang
Responsible party
Weibing Tang (Clinical Professor, Nanjing Children's Hospital) — Sponsor-investigator
First posted
Jun 18, 2023
Start date
May 20, 2017
Primary completion
Jul 1, 2023 (estimated)
Completion
Jul 1, 2023 (estimated)
Last update
Jun 18, 2023

Study contacts

Changgui Lu, Dr
Contact
luchanggui1984@163.com
13770848448
Weibing Tang, Dr
study director · Children's Hospital of Nanjing Medical University
Weibing Tang, Dr
principal investigator · Children's Hospital of Nanjing Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion